

Special Issue

Molecular Basis and Translational Research in Genetic Myopathies

Message from the Guest Editors

Genetic myopathies are inherited disorders which primarily affect skeletal muscles. These diseases constitute a heterogeneous group comprising a wide range of disorders.

Our goal for this Special Issue is to highlight new discoveries regarding the cellular and molecular targets in genetic myopathies for new therapeutic approaches to stop disease progression and improve patient quality of life. *Biomedicines* invites authors to contribute original research and review articles. Topics that could be considered include, but are not limited to:

- Molecular basis of genetic myopathies;
- Muscular dystrophies;
- Congenital myopathies;
- Metabolic myopathies;
- Mitochondrial myopathies;
- Inflammatory myopathies with a genetic basis;
- Genetic myopathy pathogenesis;
- Specific therapeutic approaches;
- Preclinical studies regarding genetic myopathies;
- Clinical studies/clinical trials on genetic myopathies.

Guest Editors

Dr. Emilia Manole

National Institute of Pathology "Victor Babes", 050096 Bucharest, Romania

Dr. Gisela Gaina

"Victor Babes" National Institute of Pathology, Bucharest, Romania

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/183623

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).